Overview

In this white paper, you will find 10 transferable lessons from the bioprocessing industry to cell and gene therapy manufacturing.

As the cell therapy industry continues to develop and grow, bringing more cutting-edge technologies to the market, the opportunity to take advantage of the benefits single-use-technology (SUT) have already demonstrated in protein, mAb, and vaccine manufacturing will only increase. Given the product requirements and the personalized nature of autologous cell therapies, there is really no alternative to SUTs.

Tremendous knowledge of SUT applications and capabilities exists within the biopharma manufacturers, within the SUT manufacturers, as well as in industry organizations such as PDA, ISPE, BPOG, and BPSA. Many lessons can be learned from the application of SUTs in these markets.